Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $61.50M
• Dividend Yield: N/A
• Average Volume (3M): 14.83K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.61
• Revenue Growth: 34.04%
• EPS Growth: 55.34%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 9,967,381
• 10 Day Avg. Volume: 9,637
• 30 Day Avg. Volume: 14,831
• PEG Ratio: -0.07
• Price to Book (P/B): -0.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.20
• Enterprise Value/Market Cap: 0.37
• Enterprise Value/Revenue: 51.23
• Enterprise Value/Gross Profit: -469.62
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $11.00
• Price Target Upside: 78.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: $5.50 ▼(-10.86%Downside)

The overall stock score reflects significant financial challenges, balanced by positive corporate developments. The most critical factor is the poor financial performance, which is a major concern. However, recent technological breakthroughs and funding initiatives show promise and potential for future growth, providing some support to the stock's outlook.

Positive Factors

Clinical Development

SER-252 has the potential to become the best-in-class drug in advanced Parkinson's Disease.

Regulatory Approval

The company's clear vision for SER-252's regulatory approval path includes potential for 505(b)2, which could reduce timelines and costs.

Negative Factors

Financial Needs

Serina will require additional capital to support development, as current cash is expected to last through 2Q25.

Market Challenges

Current formulations of apomorphine like APOKIN and ONAPGO have severe adverse events, which can hinder treatment compliance.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics (SER) is a biotechnology company specializing in the development of polymer-based drug delivery platforms. The company focuses on enhancing the efficacy and safety of existing pharmaceuticals by utilizing its proprietary Polyoxazoline (POZ) technology to improve drug solubility, stability, and delivery. Serina Therapeutics operates primarily within the pharmaceutical and biotechnology sectors, offering innovative solutions to streamline drug formulation and administration.

How the Company Makes Money

Serina Therapeutics makes money through licensing agreements and partnerships with pharmaceutical companies interested in utilizing its proprietary POZ technology to enhance their drug products. These collaborations often involve upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, Serina may engage in research and development contracts, where they apply their technology to develop customized drug delivery solutions for clients, generating revenue through service fees. Partnerships with larger pharmaceutical companies also provide strategic funding, supporting the company's ongoing research and development efforts.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics faces severe financial challenges with significant losses reflected in the income statement, a strained balance sheet due to high liabilities and negative equity, and weak cash flow due to negative free cash flow and operational inefficiencies.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.00K	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	-48.00K	-138.00K	-29.00K	355.00K	2.89M	-1.23M
EBITDA	-553.00K	-10.49M	5.92M	-2.60M	-7.35M	-8.74M
Net Income	-939.00K	-11.14M	5.27M	-2.68M	-8.68M	-10.87M
Balance Sheet
Total Assets	6.73M	6.72M	11.96M	858.04K	1.84M	3.92M
Cash, Cash Equivalents and Short-Term Investments	4.27M	3.67M	345.00K	532.23K	1.31M	527.00K
Total Debt	227.00K	268.00K	4.37M	1.81M	398.17K	6.30M
Total Liabilities	5.17M	6.22M	6.61M	38.64M	36.95M	9.32M
Stockholders Equity	1.70M	641.00K	5.47M	-37.78M	-35.11M	-5.12M
Cash Flow
Free Cash Flow	-19.89M	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-19.88M	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-8.00K	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	15.40M	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Positive. The current price of 6.17 is above the 20-day moving average (MA) of 5.90, above the 50-day MA of 5.77, and above the 200-day MA of 5.54, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 57.79 is Neutral, neither overbought nor oversold. The STOCH value of 78.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
KRON	51 Neutral	$53.65M	―	-59.49%	―	21.15%	46.44%
SER	50 Neutral	$61.50M	―	45.59%	―	34.04%	55.34%
PDSB	50 Neutral	$64.45M	―	-119.22%	―	―	25.51%
GANX	46 Neutral	$58.99M	―	-290.21%	―	-100.00%	44.28%
VRCA	41 Neutral	$48.34M	―	-1546.58%	―	-19.45%	31.22%
STRO	38 Underperform	$61.99M	―	-679.15%	―	-56.88%	-57.57%

Serina Therapeutics Corporate Events

Serina Therapeutics Appoints Dr. Stephen Brannan to Board

On May 22, 2025, Serina Therapeutics announced the appointment of Dr. Stephen Brannan to its Board of Directors, bringing extensive expertise in neuroscience and neuropsychiatry drug development. Dr. Brannan’s experience, notably his role in the successful development of KarXT at Karuna Therapeutics, aligns with Serina’s focus on long-acting CNS treatments. Concurrently, Remy Gross departed from the Board, transitioning to a consulting role, having contributed significantly to Serina’s growth.

The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Serina Therapeutics Unveils Breakthrough in LNP Technology

On April 15, 2025, Serina Therapeutics announced that its Chief Development Officer, Dr. Randall Moreadith, presented at the LNP Formulation & Process Development Summit in Boston. The presentation highlighted a significant advancement in lipid nanoparticle (LNP) technology, where the company has identified a PEOZ-lipid capable of replacing the PEG-lipid in standard LNP formulations. This breakthrough addresses the high incidence of anaphylaxis associated with PEG-lipids in mRNA vaccines and other therapies, potentially improving safety and efficacy for patients.

Serina Therapeutics Secures $5M for Parkinson’s Treatment

On April 8, 2025, Serina Therapeutics announced a $5 million private placement of securities to support the development of SER-252, its lead candidate for advanced Parkinson’s disease. This funding will aid in initiating a Phase 1 clinical trial for SER-252, which uses Serina’s POZ technology to provide continuous dopaminergic stimulation, potentially offering significant benefits to patients.

Serina Therapeutics CEO to Present at Innovation Conference

On April 7, 2025, Serina Therapeutics announced that its CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The presentation will highlight the company’s advancements, particularly the POZ Platform and the upcoming clinical trial of SER-252 for Parkinson’s disease. This announcement underscores Serina’s strategic positioning in the biotechnology sector and its potential impact on treatment options for Parkinson’s disease, with SER-252 projected to achieve significant market success.